Skip to NavigationSkip to content

Business Services

Top Ten most popular articles on this week!

On 12 July news broke that Novartis, Amgen and Banner’s Alzheimer’s Institute were discontinuing a trial into investigational compound CNP520 after those taking it seemed to get worse. The news comes as yet another setback in the field as researchers saw another drug fail to take ground against the disease.

Dr John McHutchinson steps down from Gilead with $1.1 million goodbye

Published on: 18/07/19

Gilead has said that Dr John McHutchison is stepping down after nine years at the firm.

Gilead’s Chief Scientific Officer and Head of Research and Development has decided to leave the company next month, Gilead said.

Under McHutchinson, Gilead developed five new hepatitis drugs, which have been used by as many as 3.2 million people around the world.

Novartis CEO sets aside $700 million to settle bribery lawsuit

Vas Narasimhan, Novartis’ CEO, has set aside $700 million to settle a bribery lawsuit in the United States.

Speaking in a conference call, Narasimhan said he sought to bring an end to the whistle-blower lawsuit in which Novartis was accused of bribing doctors to boost subscriptions of its drugs.

“Consistent with our efforts to resolve our legacy compliance-related allegations, right now we’re working in settlement discussions to resolve the civil suit...on speaker programs and other promotional events that happened between 2002 and 2011”

Darius Hughes, Head of Vaccines Business Unit UK, Pfizer

Published on 15/07/19 at 10:56am

“Vaccines provide a unique opportunity to have a positive effect on hundreds of thousands of people” - Darius Hughes, Head of Vaccines Business Unit UK, Pfizer

Tell us about your career.  How did you find your way into the position you’re in today?

Top Ten most popular articles on this week!

This week’s most popular story covered news of Trump’s claims that he will introduce an executive order to ensure the United States pays the lowest drug prices in the world. The claim comes amid lively debate around drug pricing in the United States.

Across the pond, the UK Government said it would give boys the HPV vaccine in an effort to tackle cancers. The NHS also said it would try out a subscription style payment model for antibiotics in seeking to tackle the global crisis of antimicrobial resistance (AMR).

GSK hires computational drug design expert Dr Kim Branson as new head of machine learning and AI

Published on: 10/07/19

British multinational GlaxoSmithKline have hired computational drug design expert Dr Kim Branson as the company’s new Senior Vice President, Global Head of Artificial Intelligence and Machine Learning.

In his new role, the biotech veteran will oversee projects which use AI to identify novel targets for potential medicines.

Dr Branson brings to the role more than 15 years’ worth of experience in biotech and academia having held positions at a number of Silicon Valley firms including Gliimpse, Lumia and Hessian Informatics.

Insider Interview: A roadblock for counterfeit drugs?

Published on 08/07/19 at 12:32pm

Dr Thomas Endress, Founder, and Dr Frederic Berkermann, co-?Founder, of a new technology being developed at the Merck Innovation Center explain the benefits of a novel solution whixch leverages blockchain to reinforce drug counterfeiting precautions and countermeasures.

Can you provide a bit of background on blockchain and explain the basics of how it works?

ABPI Chief Executive Mike Thompson to retire by the end of 2019

The Association of the British Pharmaceutical Industry (ABPI) has announced that its Chief Executive Mike Thompson is to retire from his role by the end of this year.

His decision to leave the association marks the end of a three-year run beginning in March 2016, when stepped in to take up the mantle from Alison Clough, who had served as the acting Chief Executive for much of 2015.

Top Ten most popular articles on this week!

The top story of this week covered Novartis’ announcement that they did not send chemicals that could be used to make chemical weapons to Syria. The announcement came as a relief to shareholders as shares in chemical distributor Brenntag plummeted after it was found they had send chemical weapon precursors to the war torn country.  

Living with mal de debarquement syndrome

Published on 01/07/19 at 11:40am
Dr Dai, Dr Mucci and Dr Yakushin at the 2018 Barany Society Meeting

Polly Moyer reflects on her experiences living with the rare condition mal de debarquement syndrome, and discusses how connecting with other rare disease patients in professional and personal contexts has helped her maintain optimism. 

Can you provide a bit of background on mal de debarquement syndrome?

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches